Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status

The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers

(2021) Sheila F Lumley et al.   CLINICAL INFECTIOUS DISEASES

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

(2021) Merryn Voysey et al.   LANCET

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

(2021) Charlotte Manisty et al.   LANCET

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

(2021) Florian Krammer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

(2020) Corine H. GeurtsvanKessel et al.   Nature Communications

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study

(2020) David W Eyre et al.   eLife

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET